Summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… may leads to lower adherence to iron chelation therapy rates (n, N) compared with DFP plus deferasirox (DFX) (low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.84 [0.72, 0.99]
1 study · 96 participants
Low

DFP and DFO vs DFP and DFX

SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
1 [0.06, 16.22]
1 study · 96 participants
Very low

It is very uncertain whether summary of findings: Comparison 7 ‐ deferiprone (DFP) plus… changes all‐cause mortality ‐ at 1 year ‐ trial end compared with DFP plus deferasirox (DFX) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RD 0
1 study · 96 participants
Very low

DFP and DFO vs DFP and DFX

Sustained adherence

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DFP and DFO vs DFP and DFX

QoL

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
GRADE not reported

Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo

Change in Ejection fraction (%) · people with DMD or BMD (ages not stated)

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo

Size of metabolically abnormal areas of myocardium · people with DMD or BMD (ages not stated)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo

Improvements in quality of life measures · people with DMD or BMD (ages not stated)

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Growth hormone (0.23 mg/kg/week for DMD and 0.07 mg/kg/week in BMD SC injection) vs placebo

Adverse events · people with DMD or BMD (ages not stated)

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Depressive symptoms · treatment‐resistant depression in adults

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 102 participants
Low

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI) with busiprone (20… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI) with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 0.6 [0.23, 1.53]
1 study · 108 participants
Low

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Response to treatment ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Remission ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

Quality of life ‐ not measured · treatment‐resistant depression in adults

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found